Project Grant R01CA279040
- This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...
- This Project Grant award, valued at $305,000.00 and provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, supports the development and commercialization of a novel light-activatable nanoplatform for the targeted delivery of photodynamic therapy (PDT) and chemotherapy to treat peritoneal metastasis. The nanoplatform is designed to selectively eliminate cancer cells that could not be removed by surgery, with the goal of...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...
- This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...
- This $406,500 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel intratumoral delivery system by Absco Therapeutics, Inc. (Abscotx) to enhance solid tumor immunotherapy. The Oncolymer platform utilizes a thermoresponsive hydrogel and FDA-approved imaging agent to enable sustained, localized delivery of therapeutic agents like immune-sensitizing siRNA and the TLR7 agonist imiquimod. Preclinical studies have...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support research at the University of Texas MD Anderson Cancer Center to develop mathematical models and computational tools for optimizing the delivery of a transarterial ablative therapy for treating hepatocellular carcinoma (liver cancer). The $536,836 award will fund a multi-disciplinary research effort to formulate mathematical models that capture the complex physical and...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- The National Cancer Institute awarded Accure Health Inc. a $400,000 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to develop a novel technology platform for targeted delivery of RNA therapeutics to gastrointestinal cancers. The project aims to engineer membrane vesicles derived from the cyanobacterium Spirulina to improve the efficacy and oral delivery of RNA-based cancer treatments. Key components include applying AI-powered protein design algorithms to...
- The National Cancer Institute (NCI) has awarded a $727,904 Cooperative Agreement to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, under the Cancer Biology Research program (CFDA 93.396). The purpose of this 23-month award, with a start date of August 11, 2025, is to engineer probiotic bacteria (E. coli Nissle 1917) to identify precancerous lesions, characterize novel stage-specific immune targets, and design immunomodulatory...
DEVELOPMENT OF NANOFUNCTIONALIZED CYBORG C-NOVYI NT FOR IMAGE GUIDED TRANS-ARTERIAL BACTERIOLYTIC EMBOLIZATION OF COLORECTAL LIVER METASTASIS - PROJECT SUMMARY THE LONG-TERM OBJECTIVE OF THIS PROPOSAL IS TO IMPROVE THE PROGNOSIS OF PATIENTS WITH COLORECTAL LIVER METASTASES (CRLM). ONLY 15% OF THESE PATIENTS ARE CANDIDATES FOR SURGICAL RESECTION DUE TO THE NUMBER, SIZE, AND LOCATION OF THEIR LIVER METASTASES. EVEN FOR RESECTION CANDIDATES, SURVIVAL RATES REMAIN DISMAL. IMPROVED APPROACHES ARE DESPERATELY NEEDED TO TREAT THIS DEVASTATING AND INCREASINGLY PREVALENT DISEASE. IT HAS BEEN RECOGNIZED THAT ANAEROBIC BACTERIA CAN PROLIFERATE ONLY IN THE HYPOXIC REGIONS OF SOLID TUMORS SUBSEQUENTLY LYSING TUMOR CELLS RESULTING IN MARKED DE-BULKING AND OFTEN COMPLETE REGRESSION. THE FAILURE OF CHEMOTHERAPIES FOR A BROAD RANGE OF TUMOR ETIOLOGIES, INCLUDING CRLM, HAS LED TO A REJUVENATED INTEREST IN THE DEVELOPMENT OF BACTERIOLYTIC APPROACHES FOR THE TREATMENT OF SOLID TUMORS. MOST RECENTLY, THE MODIFIED ANAEROBE CLOSTRIDIUM NOVYI-NT WAS IDENTIFIED AS AN IDEAL STRAIN FOR BACTERIOLYTIC THERAPY. PRE-CLINICAL ANIMAL MODEL STUDIES HAVE DEMONSTRATED THE STRIKING POTENTIAL OF C. NOVYI-NT TO ERADICATE SOLID TUMORS. RECENT CLINICAL TRIALS HAVE INVESTIGATED THESE BACTERIOLYTIC APPROACHES FOR THE TREATMENT OF PATIENTS WITH A BROAD RANGE OF TUMOR ETIOLOGIES. INITIAL RESULTS FROM THESE STUDIES HAVE BEEN HIGHLY PROMISING. HOWEVER, THESE STUDIES HAVE ALSO IDENTIFIED CRITICAL QUESTIONS THAT MUST BE ADDRESSED TO MAXIMIZE THE EFFICACY OF BACTERIOLYTIC APPROACHES, PARTICULARLY FOR THE TREATMENT OF CRLM: 1) SYSTEMIC INTRA-VENOUS (IV) DOSING OF C. NOVYI-NT SPORES CAN PRODUCE POSITIVE RESPONSES BUT THE RESIDUAL TUMOR TISSUES IN NORMOXIC AREA, ASSOCIATED TOXICITIES WITH LOW TARGETING EFFICACY AND REQUIREMENT FOR EXTENDED REGIMEN OF ANTIBIOTICS POST-THERAPY MAY BE PROBLEMATIC. FOR CRLM, SELECTIVE LIVER-DIRECTED TRANSCATHETER INTRA-ARTERIAL (IA) ADMINISTRATION SHOULD BE FEASIBLE. FURTHERMORE, GIVEN THE PREFERENTIAL ARTERIAL BLOOD SUPPLY OF CRLM, HYPOXIA AND SELECTIVE ANAEROBE GERMINATION COULD CONCEIVABLY BE ENHANCED VIA FOLLOW-UP INFUSION OF EMBOLIC MATERIALS TO BLOCK BLOOD FLOW TO THESE METASTASES. THE SALIENT COMBINATION OF THE LATTER APPROACHES WE HAVE NOW DUBBED `TRANSARTERIAL BACTERIOLYTIC EMBOLIZATION' (TBE). 2) OBLIGATE ANAEROBE C. NOVYI-NT SPORES GERMINATE IN ONLY HYPOXIC REGIONS AND DESTROY TUMOR CELLS VIA SECRETION OF LIPASES AND PROTEASES. ACCURATE DELIVERY OF C. NOVYI-NT SPORES TO THESE HYPOXIC REGIONS AND SUBSEQUENT TUMOR COLONIZATION WILL BE CRITICAL TO ACHIEVE POSITIVE OUTCOMES. IMAGING THE DYNAMIC DISTRIBUTION OF C. NOVYI-NT SPORES AND GERMINATED ANAEROBES (TRANSCATHETER IA DELIVERY TO THE TUMORS AND SUBSEQUENT COLONIZATION IN TUMOR) SHOULD CRITICALLY PERMIT A) INTRA-PROCEDURAL OPTIMIZATION DURING TARGETED ADMINISTRATION AND B) EARLY PREDICTION OF LONGITUDINAL OUTCOMES. THROUGH THIS COLLABORATIVE PROJECT BUILDING UPON OUR INTER-DISCIPLINARY STRENGTHS IN NANO/BIO INTERFACES, NANOMEDICINE, INTERVENTIONAL ONCOLOGY, AND RADIOLOGY, WE SEEK TO DEVELOP A NEW NANO-FUNCTIONALIZED CYBORG C. NOVYI-NT AND POWERFUL NEW APPROACH FOR IMAGE-GUIDED TRANS-ARTERIAL BACTERIOLYTIC THERAPY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $35.7k | 7/7/25 | ||
| Not listed | $321.1k | 3/26/25 | ||
| Not listed | $321.1k | 3/26/25 | ||
| Not listed | $357.2k | 5/3/24 | ||
| Not listed | $357.2k | 5/3/24 |